-
Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463
16 Oct 2025 06:30 GMT
… -in-class OncoMimics™ immunotherapies to treat cancer, … for its lead OncoMimics™ immunotherapy, EO2463. The decision … that limits many cancer immunotherapies. Each product combines … developing breakthrough OncoMimics™ Immunotherapeutics for cancer. The …
-
ESMO 2025: Lunit’s AI tool predicts immunotherapy response across cancer types
16 Oct 2025 02:49 GMT
… patients’ response to immunotherapy across cancer types.
… likely to benefit from immunotherapy combinations, according to … treatment selection between immunotherapy combinations and targeted … will truly benefit from immunotherapy – whether in colorectal …
-
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
16 Oct 2025 00:19 GMT
… action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25 … .com
844-916-0895 MoonLake Immunotherapeutics (MLTX) Securities Class Action: The …
-
MoonLake Immunotherapeutics (MLTX) Investors with Substantial Losses Have Opportunity to Lead the MoonLake Class Action Lawsuit -- RGRD LLP
15 Oct 2025 19:39 GMT
… lawsuit – captioned Bridgewood v. MoonLake Immunotherapeutics, No. 25-cv-08500 (S … purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and … .rgrdlaw.com/cases-moonlake-immunotherapeutics-class-action-lawsuit-mltx.html …
-
MOONLAKE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm
15 Oct 2025 18:46 GMT
… you purchased or acquired MoonLake Immunotherapeutics common stock between March 10 … has been filed against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) ( … purchased or otherwise acquired MoonLake Immunotherapeutics common stock between March 10 …
-
Immunotherapy Developer Expands Beyond Myeloid Cells and Cancer
15 Oct 2025 18:04 GMT
… scalable, redosable, off-the-shelf immunotherapies that provide greater effectiveness against … gastroesophageal junction (GEJ) cancer using immunotherapy; and MT-303, a candidate …
-
Immunotherapy Could Enable Periods of Drug-Free HIV Suppression
15 Oct 2025 15:44 GMT
… 1 clinical trial of an immunotherapy commonly used in cancer offer … , we’ve tested a cancer immunotherapy drug -an anti–PD-1 … combine this approach with other immunotherapies and to determine which individuals …
-
Onc Nurse On Call: Immunotherapy With Kristin Daly
15 Oct 2025 15:35 GMT
… , Daly discusses all things immunotherapy, from pan-cancer therapy … on common types of immunotherapies and how to handle … s attention.
The complexity of immunotherapy can, in turn, complicate … be very vigilant about: immunotherapy-related adverse effects in …
-
SHAREHOLDER ALERT: MoonLake Immunotherapeutics Sued For Securities Fraud by Block & Leviton LLP; December 15 Deadline To Seek To Serve As Lead Plaintiff
15 Oct 2025 15:18 GMT
… action lawsuit today against MoonLake Immunotherapeutics (Nasdaq: MLTX), along with … purchased or otherwise acquired MoonLake Immunotherapeutics common stock between March … purchased or otherwise acquired MoonLake Immunotherapeutics stock during the Class …
-
Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer
14 Oct 2025 12:39 GMT
… advance innovative viral immunotherapies for patients with … -shelf, multimodal viral immunotherapies that elicit an individualized … -stage multimodal biological immunotherapy platforms based on novel … -development-of-viral-immunotherapies-to-fight-cancer- …